Björkenstam Marie, Bobbio Emanuele, Polte Christian L, Hjalmarsson Clara, Bergh Niklas, Omerovic Elmir, Bollano Entela
Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden
Institute of Medicine, Department of Molecular and Clinical Medicine, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden.
Open Heart. 2025 Apr 4;12(1):e003050. doi: 10.1136/openhrt-2024-003050.
Acute myocarditis (AM) is a disease with variable prognosis, ranging from complete recovery to end-stage heart failure (HF) and death but often challenging to differentiate from unexplained acute chest pain (UCP) in the acute setting. This study examines the short-tem and long-term outcomes of AM compared with UCP, focusing on the risk of HF development.
We used the Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies-registry to identify patients >16 years admitted to hospital between 1 January 1998 and 31 December 2018 with either AM or UCP. Patients were followed for outcomes including mortality, rehospitalisation and HF development over both short-term (30 days) and long-term periods. Cox proportional hazards models were used to compare the risks, adjusting for demographic and clinical-related factors.
A total of 3792 patients with AM and 109 934 patients with UCP were included. Median follow-up time was 7.8 years (Q1, Q3; 3.4, 12.3). AM patients were younger compared with UCP patients, median age 37 years (Q1, Q3; 26, 52) vs 59 years (Q1, Q3; 49, 69) and more likely to be men (79.9% vs 51.4%, p<0.001). Comorbidity burden was less pronounced within the AM cohort. Chest pain was the most common presenting symptom in both groups. Mortality rate at 30 days (OR 3.75, 95% CI 1.9 to 7.3, p<0001) as well as long term (OR 2.0, 95% CI 1.69 to 2.39, p<0.001) were significantly higher in AM patients compared with UCP. AM patients were more likely to develop HF during follow-up (OR 2.3, 95% CI 1.81 to 2.93, p<0001).
AM is associated with worse short-term and long-term outcomes compared with UCP, including a higher risk of developing HF even after the first year.
急性心肌炎(AM)是一种预后各异的疾病,从完全康复到终末期心力衰竭(HF)及死亡,但在急性期常难以与不明原因的急性胸痛(UCP)相鉴别。本研究比较了AM与UCP的短期和长期预后,重点关注HF发生风险。
我们使用瑞典心脏病循证护理强化网络系统(Swedish Web System for Enhancement of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies)注册数据库,确定1998年1月1日至2018年12月31日期间因AM或UCP入院的16岁以上患者。对患者进行随访,观察短期(30天)和长期的结局,包括死亡率、再住院率和HF发生情况。采用Cox比例风险模型比较风险,并对人口统计学和临床相关因素进行校正。
共纳入3792例AM患者和109934例UCP患者。中位随访时间为7.8年(第一四分位数,第三四分位数;3.4,12.3)。与UCP患者相比,AM患者更年轻,中位年龄37岁(第一四分位数,第三四分位数;26,52)对59岁(第一四分位数,第三四分位数;49,69),且男性比例更高(79.9%对51.4%,p<0.001)。AM队列中的合并症负担较轻。胸痛是两组最常见的首发症状。与UCP患者相比,AM患者30天死亡率(比值比3.75,95%置信区间1.9至7.3,p<0.001)以及长期死亡率(比值比2.0,95%置信区间1.69至2.39,p<0.001)显著更高。AM患者在随访期间更易发生HF(比值比2.3,95%置信区间1.81至2.93,p<0.001)。
与UCP相比,AM的短期和长期结局更差,包括即使在第一年之后发生HF的风险也更高。